Small Cell Lung Cancer Information Part 3
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
This final installment in the series covers additional small cell lung cancer (SCLC) treatment information for patients and families exploring options in Japan. As SCLC treatment continues to advance — with newer agents including lurbinectedin, tarlatamab, and combination immunotherapy regimens entering clinical practice — Japanese medical institutions remain at the forefront of providing comprehensive oncology care. Medical Supporter assists international patients in navigating these treatment options and connecting with appropriate Japanese specialists.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4